Eyepoint Pharmaceuticals Launches $150 Million Offering Amid Stock Decline

Eyepoint Pharmaceuticals has launched a $150 million public offering aimed at funding future projects, despite a recent decline in its stock value. While the offering is intended to enhance financial stability and support new developments, concerns about share dilution and the company's financial health have emerged among investors, impacting overall confidence.